Arcutis Biotherapeutics
ARQT
187 hedge funds and large institutions have $1.18B invested in Arcutis Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 59 increasing their positions, 55 reducing their positions, and 29 closing their positions.
158% more call options, than puts
Call options by funds: $7.02M | Put options by funds: $2.72M
66% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 29
11% more funds holding
Funds holding: 168 → 187 (+19)
7% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 55
6% more capital inflows, than outflows
Capital inflows: $183M | Capital outflows: $173M
0.58% more ownership
Funds ownership: 108.71% → 109.29% (+0.58%)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rubric Capital Management (New York)
New York
|
+$20.9M |
| 2 |
Suvretta Capital Management
New York
|
+$19.2M |
| 3 |
BlackRock
New York
|
+$17.8M |
| 4 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$11.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$33M |
| 2 |
Farallon Capital Management
San Francisco,
California
|
-$15.9M |
| 3 |
Braidwell
Stamford,
Connecticut
|
-$12.9M |
| 4 |
Stempoint Capital
New York
|
-$11.2M |
| 5 |
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$8.87M |
ARQT Hedge Fund Activity: Q2 2024 in Review
187 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2024, worth a combined $1.18B — down 5% from $1.24B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new ARQT positions and 29 closed out — a net gain of 19 holders — while 59 added to existing stakes and 55 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $20.9M. The largest seller was State Street, cutting an estimated $33M.
- 187 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2024, up from 168 in Q1 2024.
- Funds reported $1.18B of Arcutis Biotherapeutics stock for Q2 2024, down 5% quarter-over-quarter.
- 48 funds opened new Arcutis Biotherapeutics positions in Q2 2024 and 29 closed out, a net change of +19 holders.
- The largest Arcutis Biotherapeutics buyer in Q2 2024 was Rubric Capital Management (New York), an estimated $20.9M added.
- The largest Arcutis Biotherapeutics seller in Q2 2024 was State Street, an estimated $33M sold.
Based on aggregated 13F filings for Q2 2024.